Neuberger Berman Group
IOVA icon

Neuberger Berman Group’s Iovance Biotherapeutics IOVA Stock Holding History

Neuberger Berman Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
50,280
+3,621
+8% +$13.8K ﹤0.01% 2161
2026
Q1 		$164K Buy
46,659
+7,587
+19% +$24.3K ﹤0.01% 2025
2025
Q4 		$107K Buy
39,072
+5,605
+17% +$13K ﹤0.01% 2011
2025
Q3 		$72.6K Buy
33,467
+589
+2% +$1.39K ﹤0.01% 1985
2025
Q2 		$56.5K Sell
32,878
-1,121
-3% -$2.79K ﹤0.01% 1987
2025
Q1 		$113K Buy
33,999
+8,879
+35% +$45.8K ﹤0.01% 1871
2024
Q4 		$186K Buy
25,120
+14,716
+141% +$136K ﹤0.01% 1806
2024
Q3 		$97.7K Buy
10,404
+370
+4% +$3.51K ﹤0.01% 1842
2024
Q2 		$80.5K Buy
+10,034
New +$108K ﹤0.01% 1822
2021
Q2 		– Sell
-398,484
Closed -$12.6M – 1791
2021
Q1 		$12.6M Buy
398,484
+341,409
+598% +$14.2M 0.01% 784
2020
Q4 		$2.65M Sell
57,075
-53,000
-48% -$2.1M ﹤0.01% 1057
2020
Q3 		$3.62M Buy
110,075
+15,000
+16% +$460K ﹤0.01% 928
2020
Q2 		$2.61M Buy
95,075
+59,975
+171% +$1.97M ﹤0.01% 958
2020
Q1 		$1.05M Buy
+35,100
New +$930K ﹤0.01% 1086
2018
Q3 		– Sell
-74,000
Closed -$947K – 1659
2018
Q2 		$947K Buy
+74,000
New +$1.08M ﹤0.01% 1247

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Neuberger Berman Group's IOVA Position: Q2 2026 in Review

Neuberger Berman Group increased its Iovance Biotherapeutics (IOVA) stake by 7.8% in Q2 2026, buying an estimated $13.8K and bringing the position to 50,280 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

Neuberger Berman Group first reported a position in IOVA in Q2 2018 and has held it in 15 quarters since. The position peaked at $12.6M in Q1 2021. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Neuberger Berman Group held 50,280 shares of Iovance Biotherapeutics worth $209K as of Q2 2026.
  • Neuberger Berman Group bought 3,621 Iovance Biotherapeutics shares in Q2 2026, an estimated $13.8K.
  • Iovance Biotherapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2161 holding.
  • Neuberger Berman Group first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 15 quarters since.
  • Neuberger Berman Group's Iovance Biotherapeutics position peaked at $12.6M in Q1 2021.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.